

I hereby certify that this correspondence is being transmitted via Electronic Filing System to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on October 6, 2006

PATENT


Oksana Buynitzky
Date of Signature October 6, 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Gonda et al.

Group Art Unit: Not Assigned

Serial No.: 10/550,533

Examiner: Not Assigned

Filed: September 23, 2005

Docket No.: 1386/21

For: METHOD FOR IDENTIFYING NUCLEIC ACID MOLECULES ASSOCIATED WITH ANGIOGENESIS

SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. 1.56, 1.97, and 1.98, applicants' undersigned attorney brings to the attention of the Patent and Trademark Office the references listed on the attached form PTO-1449. Copies of the references A-AF as well as Form PTO-1449 are attached hereto as electronic files in PDF format.

This is not to be construed as a representation that a search has been made or that a reference is relevant merely because cited.

Early passage of the subject application to issue is earnestly solicited.

Atty. Docket No.: 1386/21


The Commissioner is hereby authorized to charge any fees associated with the filing of this correspondence to Deposit Account No. 50-0426.

Respectfully submitted,

JENKINS, WILSON, TAYLOR & HUNT, P.A.

Date: October 6, 2006

By:



Arles A. Taylor, Jr.
Registration No. 39,395

Customer No.: 52354

1386/21 AAT/JD/omb

Enclosures

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office List of Documents Cited by Applicant	Application No.:	10/550,533
	Filing Date:	September 23, 2005
	First Named Inventor:	Gonda Thomas John
	Group:	TBA
	Examiner:	TBA
Page 1 of 4	Attorney Docket No.:	1386/21

U.S. PATENT DOCUMENTS

Examin er Initials	Cite No.	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, where relevant passages or relevant figures appear

FOREIGN PATENT DOCUMENTS

Examin er Initials	Cite No.	Document Number (country code, no., kind code (if known))	Publication Date	Name of Patentee or Applicant	Pages, columns, lines where relevant passages appear	T
	A	EP 1293569	03/19/2003	Helix Research Institute; Research Association for Biotechnology		
	B	WO 00/55633	09/21/2000	EOS Biotechnology, Inc.		
	C	WO 00/58495	10/05/2000	Human Genome Sciences, Inc.		
	D	WO 00/73509	12/07/2000	Incyte Genomics, Inc.		
	E	WO 01/07611	02/01/2001	GENENTECH, Inc.		
	F	WO 01/11086	02/15/2001	EOS Biotechnology, Inc.		

EXAMINER _____ DATE CONSIDERED _____

*Examiner Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office List of Documents Cited by Applicant	Application No.:	10/550,533
	Filing Date:	September 23, 2005
	First Named Inventor:	Gonda Thomas John
	Group:	TBA
	Examiner:	TBA
Page 2 of 4	Attorney Docket No.:	1386/21

	G	WO 01/60860	08/23/2001	Millennium Predictive Medicine, Inc.		
	H	WO 01/73027	10/04/2001	CORIXA CORPORATION		
	I	WO 01/96388	12/20/2001	CORIXA CORPORATION		
	J	WO 02/08288	01/31/2002	GENENTECH, Inc.		
	K	WO 02/098358	12/12/2002	EOS Biotechnology, Inc.		
	L	WO 02/102235	12/27/2002	EOS Biotechnology, Inc.		
	M	WO 02/29103	04/11/2002	GENE LOGIC, Inc.		
	N	WO 03/000296	01/03/2003	ISIS Innovations Limited		
	O	WO 03/000727	01/03/2003	ISIS Innovations Limited		
	P	WO 03/003906	01/16/2003	EOS Biotechnology, Inc.		
	Q	WO 03/029273	04/10/2003	Whitehead Institute for Biomedical Research, Inc.		
	R	WO 03/083140	10/09/2003	St. Jude Children's Research Hospital, Inc.		
	S	WO 03/088910	10/30/2003	Rigel Pharmaceuticals, Inc.		
	Y	WO 04/007762	01/22/2004	Novartis Pharma GMBH		
	U	WO 04/020591	03/11/2004	Five Prime Therapeutics, Inc.		

EXAMINER _____ DATE CONSIDERED _____

*Examiner Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office List of Documents Cited by Applicant	Application No.:	10/550,533
	Filing Date:	September 23, 2005
	First Named Inventor:	Gonda Thomas John
	Group:	TBA
	Examiner:	TBA
Page 3 of 4		Attorney Docket No.: 1386/21

	V	WO 04/020595	03/11/2004	Five Prime Therapeutics, Inc.; RIKEN The Institute of Physical and Chemical Research; Kabushiki Kaisha DNAFORM		
	W	WO 04/039943	05/13/2004	CHIRON CORPORATION		
	X	WO 04/059001	07/15/2004	HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN		
	Y	WO 04/067778	08/12/2004	University of South Florida		
	Z	WO 05/002414	01/13/2005	MOR Research Applications Limited		
	AA	WO 05/005597	01/20/2005	Five Prime Therapeutics, Inc.; RIKEN The Institute of Physical and Chemical Research; Kabushiki Kaisha DNAFORM		
	AB	WO 05/011619	02/10/2005	Five Prime Therapeutics, Inc.		
	AC	WO 05/014854	02/17/2005	Licentia, Ltd.		
	AD	WO 05/016962	02/24/2005	GENENTECH, INC.		
	AE	WO 05/019258	03/03/2005	GENENTECH, INC.		
	AF	WO 86/03838	07/03/1986	ONCOGEN		
OTHER DOCUMENTS						

EXAMINER _____ DATE CONSIDERED _____

*Examiner Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office List of Documents Cited by Applicant	Application No.:	10/550,533
	Filing Date:	September 23, 2005
	First Named Inventor:	Gonda Thomas John
	Group:	TBA
	Examiner:	TBA
Page 4 of 4	Attorney Docket No.:	1386/21

Examin er Initials	Cite No.	Include Author (in CAPITAL LETTERS), Title, Journal, Date, Pertinent Pages, Etc.	T

EXAMINER _____ DATE CONSIDERED _____

*Examiner Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.